Gestrinone

Endometriosis is common disease characterized by the presence of endometrial tissue outside the uterus which affects approximately 10% of premenopausal women. Gestrinone is a synthetic steroid used occasionally to treat endometriosis. It acts centrally on the hypothalamic-pituitary system to suppress release of lutenizing hormone (LH) and follicle-stimulating hormone (FSH), thus reducing estrogen synthesis. It also binds to androgen (AR), progesterone (PR), and estrogen (ER) receptors in the human endometrial tissue but not to steroid hormone binding globulin or corticord-binding globulin. Gestrinone binds to AR and PR with EC50 values of approximately 20 and 30 nM, respectively. These values reflect approximately 5-6 fold lower affinity than testosterone and progesterone, the natural AR and PR ligands, for these receptors.Formal Name: 13-ethyl-17alpha-hydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one. CAS Number: 16320-04-0. Molecular Formula: C21H24O2. Formula Weight: 308.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMSO: 20 mg/ml, Ethanol: 20 mg/ml, Ethanol:PBS (pH 7.2) (1:5): 0.25 mg/ml. lambdamax: 238, 341 nm. SMILES: O[C@@]1(C#C)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3C=C[C@@]21CC)=O. InChi Code: InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1. InChi Key: BJJXHLWLUDYTGC-ANULTFPQSA-N.